The way we define Parkinson’s disease is changing. Rather than relying on observable motor symptoms, emerging biological classification systems focus on measurable biomarkers, genetic risk, and neurodegeneration — enabling earlier, more accurate diagnosis and more targeted therapies.
Atuka’s new white paper, “Redefining Parkinson’s Disease: Biological Classification and the Future of Therapeutics,” by Chief Innovation Officer Patrick Howson, PhD, provides a clear, comparative look at these new frameworks and their implications for research and therapy development.
您将从本白皮书中获得：
- Why clinical definitions of PD are insufficient for modern research
- How SynNeurGe and NSD-ISS reframe Parkinson’s as a biological continuum
- Similarities and key differences between the two approaches
- What these frameworks mean for diagnosis, trial design, and precision medicine
- Considerations and challenges for researchers, clinicians, and sponsors
为什么值得一读？
A biological definition of PD enables more homogeneous trial cohorts, earlier intervention, and better alignment between pathology and therapy. But it also raises important scientific and ethical questions that the field must navigate.
This white paper gives researchers, clinicians, and sponsors the insights they need to stay ahead of this paradigm shift.
Download the Full White Paper to understand how the biological classification of Parkinson’s is shaping the future of research and therapeutics.